128 related articles for article (PubMed ID: 24154781)
1. Benzbromarone: availability for general prescribing in New Zealand (a response to letters by Dr Lance Gravatt onbenzbromarone).
Day R; Lee H; Graham G; Williams K
N Z Med J; 2013 Sep; 126(1382):124-6. PubMed ID: 24154781
[No Abstract] [Full Text] [Related]
2. New urate-lowering therapies in Aotearoa New Zealand: a response to Dr Lance Gravatt's letter on benzbromarone hepatotoxicity.
Dalbeth N; Gow P; Stamp L; Merriman T; Stuart R; Winnard D; Lindsay K;
N Z Med J; 2013 Sep; 126(1382):120-3. PubMed ID: 24154780
[No Abstract] [Full Text] [Related]
3. Gout--is Lee's 2008 risk:benefit conclusion for benzbromarone hepatotoxicity still relevant today?
Gravatt L
N Z Med J; 2013 Sep; 126(1382):118-9. PubMed ID: 24154779
[No Abstract] [Full Text] [Related]
4. A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?
Lee MH; Graham GG; Williams KM; Day RO
Drug Saf; 2008; 31(8):643-65. PubMed ID: 18636784
[TBL] [Abstract][Full Text] [Related]
5. Benzbromarone withdrawn from the European market: another case of "absence of evidence is evidence of absence"?
Jansen TL; Reinders MK; van Roon EN; Brouwers JR
Clin Exp Rheumatol; 2004; 22(5):651. PubMed ID: 15485024
[No Abstract] [Full Text] [Related]
6. Uricosuric medications for chronic gout.
Kydd AS; Seth R; Buchbinder R; Edwards CJ; Bombardier C
Cochrane Database Syst Rev; 2014 Nov; (11):CD010457. PubMed ID: 25392987
[TBL] [Abstract][Full Text] [Related]
7. Benzbromarone in the treatment of gout.
Azevedo VF; Kos IA; Vargas-Santos AB; da Rocha Castelar Pinheiro G; Dos Santos Paiva E
Adv Rheumatol; 2019 Aug; 59(1):37. PubMed ID: 31391099
[TBL] [Abstract][Full Text] [Related]
8. Decreased incidence of diabetes in patients with gout using benzbromarone.
Niu SW; Chang KT; Ta A; Chang YH; Kuo IC; Hung CC; Chiu YW; Hwang SJ; Lin SF; Lin HY
Rheumatology (Oxford); 2018 Sep; 57(9):1574-1582. PubMed ID: 29796661
[TBL] [Abstract][Full Text] [Related]
9. International position paper on the appropriate use of uricosurics with the introduction of lesinurad.
Jansen TL; Perez-Ruiz F; Tausche AK; Richette P
Clin Rheumatol; 2018 Dec; 37(12):3159-3165. PubMed ID: 30244431
[TBL] [Abstract][Full Text] [Related]
10. Repair of Bone Erosion With Effective Urate-Lowering Therapy in a Patient With Tophaceous Gout.
Sakaguchi S
Arthritis Rheumatol; 2021 Feb; 73(2):231. PubMed ID: 32892502
[No Abstract] [Full Text] [Related]
11. Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients.
Reinders MK; van Roon EN; Houtman PM; Brouwers JR; Jansen TL
Clin Rheumatol; 2007 Sep; 26(9):1459-65. PubMed ID: 17308859
[TBL] [Abstract][Full Text] [Related]
12. Influence of urate-lowering therapies on renal handling of uric acid.
Ma L; Wei L; Chen H; Zhang Z; Yu Q; Ji Z; Jiang L
Clin Rheumatol; 2016 Jan; 35(1):133-41. PubMed ID: 25373449
[TBL] [Abstract][Full Text] [Related]
13. [Isolated or combined drug therapy of hyperuricemia?].
Mertz DP
Dtsch Med Wochenschr; 1977 Jul; 102(30):1096-7. PubMed ID: 891391
[No Abstract] [Full Text] [Related]
14. [Chronic gout. Case report of a severe course of disease].
Boxberger F; Harsch IA; Brueckl WM; Hautmann M; Baum U; Hahn EG; Wein A
Med Klin (Munich); 2003 Nov; 98(11):646-7. PubMed ID: 14631540
[No Abstract] [Full Text] [Related]
15. The efficacy and safety of citrate mixture vs sodium bicarbonate on urine alkalization in Chinese primary gout patients with benzbromarone: a prospective, randomized controlled study.
Xue X; Liu Z; Li X; Lu J; Wang C; Wang X; Ren W; Sun R; Jia Z; Ji X; Chen Y; He Y; Ji A; Sun W; Zhang H; Merriman TR; Li C; Cui L
Rheumatology (Oxford); 2021 Jun; 60(6):2661-2671. PubMed ID: 33211886
[TBL] [Abstract][Full Text] [Related]
16. Clinical images: Divergent patterns of joint remodeling following effective urate-lowering therapy in tophaceous gout.
Dalbeth N; Doyle A; McQueen FM
Arthritis Rheum; 2011 Jan; 63(1):266. PubMed ID: 20722028
[No Abstract] [Full Text] [Related]
17. Excellent response to the clinical treatment of tophaceous gout.
Caldas CA; Fuller R
Clin Rheumatol; 2007 Sep; 26(9):1553-5. PubMed ID: 17047891
[TBL] [Abstract][Full Text] [Related]
18. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
Reinders MK; Haagsma C; Jansen TL; van Roon EN; Delsing J; van de Laar MA; Brouwers JR
Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
[TBL] [Abstract][Full Text] [Related]
19. [Hyperuricemia and gout--treatment].
Gröbner W; Walter-Sack I
Dtsch Med Wochenschr; 2002 Feb; 127(5):210-3. PubMed ID: 11821994
[No Abstract] [Full Text] [Related]
20. [Uricosuric agent benzbromarone vs. allopurinol: comparable effect].
Manger B
Dtsch Med Wochenschr; 2015 Apr; 140(8):562. PubMed ID: 25945905
[No Abstract] [Full Text] [Related]
[Next] [New Search]
